CarpeDiem IAS • CarpeDiem IAS • CarpeDiem IAS •

India set to launch free nationwide HPV vaccination for adolescent girls

26 Feb 2026 GS 3 Science & Technology
India set to launch free nationwide HPV vaccination for adolescent girls Click to view full image

Context

India is set to roll out a free, voluntary nationwide Human Papillomavirus (HPV) vaccination programme targeting 14-year-old girls, marking a major step in cervical cancer prevention.

Vaccine to be used: Gardasil (Quadrivalent)

India will use Gardasil, which protects against:

  • HPV types 16 and 18 – responsible for over 80% of cervical cancer cases in India

  • HPV types 6 and 11 – responsible for most cases of genital warts

The vaccine:

  • Is non-live (does not cause HPV infection)

  • Has a strong global safety record

  • Has seen over 500 million doses administered worldwide since 2006

  • Demonstrates 93–100% effectiveness against cervical cancer caused by vaccine-covered HPV types

India will follow a single-dose regimen, in line with global scientific evidence and WHO recommendations.

Why age 14?

  • Maximum preventive benefit when given before exposure to HPV

  • Strong and durable immune response in early adolescence

  • Improves compliance and coverage

Delivery mechanism

Vaccination will be conducted exclusively at designated government health facilities, including:

  • Ayushman Arogya Mandirs (PHCs)

  • Community Health Centres

  • Sub-District and District Hospitals

  • Government Medical Colleges

Each session will:

  • Be supervised by trained medical officers

  • Include post-vaccination observation

  • Be linked to 24×7 government facilities

  • Have systems for managing rare adverse events

This design aims to strengthen safety monitoring and parental confidence.

Procurement and global partnership

India has secured vaccine supplies through a transparent, globally supported mechanism under partnership with Gavi, the Vaccine Alliance.

  • Vaccines are approved by India’s drug regulator

  • Procurement follows stringent quality and cold chain standards

  • Free access across all States and Union Territories

Disease burden in India

Cervical cancer:

  • Second most common cancer among Indian women

  • Nearly 80,000 new cases annually

  • Over 42,000 deaths each year

Persistent infection with high-risk HPV (especially types 16 and 18) causes almost all cases.

Despite being preventable through vaccination and screening, screening coverage remains low, making vaccination a critical public health intervention.

Important clarification: Vaccine is not a substitute for screening

Even with vaccination:

  • Regular Pap smears and screening remain essential

  • Vaccine does not protect against all HPV types

  • Early detection improves survival

Thus, vaccination and screening must work together.

Policy grounding

India’s strategy is based on:

  • National disease burden data

  • Global best practices

  • Recommendations of the National Technical Advisory Group on Immunisation (NTAGI)

Prelims Practice MCQs

Q. With reference to Human Papillomavirus (HPV), consider the following statements:

  1. Persistent infection with high-risk HPV types is responsible for almost all cases of cervical cancer.

  2. HPV types 16 and 18 account for more than 80% of cervical cancer cases in India.

  3. HPV infection can be caused by administration of the HPV vaccine.

Which of the statements given above is/are correct?

A. 1 and 2 only
B. 2 and 3 only
C. 1 only
D. 1, 2 and 3

Answer: A

Explanation:

  • Statement 1 is correct: Persistent infection with high-risk HPV causes almost all cervical cancer cases.

  • Statement 2 is correct: HPV 16 and 18 together account for over 80% of cervical cancer cases in India.

  • Statement 3 is incorrect: The HPV vaccine is non-live and does not cause HPV infection.

Q. With reference to the HPV vaccine being used in India’s national programme, consider the following statements:

  1. India will use a quadrivalent vaccine.

  2. The vaccine protects against HPV types 6, 11, 16 and 18.

  3. The vaccine provides protection against all cancer-causing HPV types.

Which of the statements given above is/are correct?

A. 1 and 2 only
B. 2 and 3 only
C. 1 only
D. 1, 2 and 3

Answer: A

Explanation:

  • Statement 1 is correct: India will use the quadrivalent vaccine Gardasil.

  • Statement 2 is correct: It protects against HPV types 6, 11, 16 and 18.

  • Statement 3 is incorrect: It does not protect against all cancer-causing HPV types; hence screening remains important.

Q. Consider the following statements regarding cervical cancer in India:

  1. It is the most common cancer among women in India.

  2. It is largely preventable through vaccination and early screening.

  3. India contributes a significant share of the cervical cancer burden in the WHO South-East Asia Region.

Which of the statements given above is/are correct?

A. 2 only
B. 2 and 3 only
C. 1 and 3 only
D. 1, 2 and 3

Answer: B

Explanation:

  • Statement 1 is incorrect: Cervical cancer is the second most common cancer among women in India.

  • Statement 2 is correct: It is largely preventable via HPV vaccination and screening.

  • Statement 3 is correct: India contributes a major share of the regional burden.



← Back to list